Abstract:Resistance to radiation therapy significantly affects the prognosis of solid tumors. Histone deacetylase 6 (HDAC6) is a stress-responsive lysine deacetylase that has emerged as a promising target for cancer therapy, with numerous clinical trials investigating interventions to modulate its activity. While HDAC6 appears to be linked to responses to DNA-damaging therapeutics, the reported responses and underlying mechanisms remain intriguing and varied. In this study, we elucidate a novel mechanism of radioresistance mediated by HDAC6 in non-small cell lung cancer (NSCLC). We classified nine NSCLC cell lines into three groups based on their radioresistance using survival assays and correlated this resistance with the induced expression of six deacetylases. We conducted gain-of-function experiments (GOF) using plasmid transfection and loss-of-function experiments (LOF) employing inhibitors or RNAi. Furthermore, we quantified the repair of damaged dsDNA through FACS-based GFP assays and assessed the mechanism of homologous recombination repair (HRR) end-resection via single-strand quantitative PCR. Co-immunoprecipitation assays, cancer stem cell enrichment, DNA damage-induced senescence assays, reverse-phase protein assays (RPPA), and RNA sequencing were also performed to investigate gene expression changes resulting from the loss of HDAC6. Our findings revealed that HDAC6 induction by radiation is strongly correlated with NSCLC resistance to radiation leading to CSC survival and escape from radiation led senescence LOF of HDAC6 through RNAi or inhibitors suppressed resistance, while GOF achieved through wild-type or deacetylase activity-deficient mutant transfection, induced resistance. Importantly, this resistance mechanism was independent of deacetylation activity. RNAi-mediated loss of HDAC6 reduced both HRR and non-homologous end-joining, whereas pharmacological inhibition of HDAC6 activity did not. Notably, DNA end-resection, a critical step in HRR, was decreased by RNA interference but not affected by the inhibitors. RPPA assays demonstrated that Histone demethylase 1A (LSD1/KDM1A) levels decreased significantly upon HDAC6 RNA interference but remained unaffected by pharmacological intervention. Loss of LSD1 alone resulted in decreased HRR and end-resection, likely mediated through HDAC6-induced ubiquitination. Moreover, overexpression of LSD1 rescued the HDAC6 loss-induced sensitization of NSCLCs. In summary, our study unveils a novel mechanism by which HDAC6 mediates HRR after radiation through the stabilization of LSD1. This mechanism operates independently of deacetylase activity. Therefore, our findings suggest that interventions targeting both deacetylation and non-deacetylation roles of HDAC6 should be considered to overcome HDAC6-derived radioresistance in NSCLCs and enhances the radiation therapy efficacy. Citation Format: Sojung Ha, Hyejin Kim, Hani Lee, Seokgyeong Choi, Ho-young Lee, Woo-Young Kim. HDAC6 mediates the radioresistance of NSCLC through LSD1, independent of its own deacetylation activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2883.

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

Histone deacetylase 6 in cancer

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Both HDAC5 and HDAC6 Are Required for the Proliferation and Metastasis of Melanoma Cells.

HDAC6 Interacts with PTPN1 to Enhance Melanoma Cells Progression.

Abstract 4582: HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization

HDAC6-dependent Deacetylation of AKAP12 Dictates Its Ubiquitination and Promotes Colon Cancer Metastasis.

Curriculum vitae of HDAC6 in solid tumors

HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.

HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma

Hdac6: Physiological Function And Its Selective Inhibitors For Cancer Treatment

HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.

Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.

The ubiquitin ligase E6AP facilitates HDAC6-mediated deacetylation and degradation of tumor suppressors

HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape

Overexpression of HDAC6 Suppresses Tumor Cell Proliferation and Metastasis by Inhibition of the Canonical Wnt/β‑catenin Signaling Pathway in Hepatocellular Carcinoma

AKT activation controls cell survival in response to HDAC6 inhibition

Abstract 2883: HDAC6 mediates the radioresistance of NSCLC through LSD1, independent of its own deacetylation activity

Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling

Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3–COX2-dependent pathway

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics